• The European Union has decided to take up an option under a supply contract with Moderna Inc (NASDAQ: MRNA) that allows the bloc to order 150 million additional COVID-19 vaccines.

• This purchase brings the European Commission's confirmed order commitment to 460 million doses.

• The announcement comes a week after CureVac BV's (NASDAQ: CVAC) COVID-19 vaccine was only 47% effective in a late-stage trial, missing the study's primary goal and casting doubt on the potential delivery of doses to the E.U.

• The additional doses will be delivered in 2022.

• The E.U. Commission said the second contract with Moderna had also been amended to allow the purchase of an updated variant booster vaccine candidate.

• Price Action: MRNA shares are up 3.34% at $215.21 during the market session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Moderna Plans To Expand COVID-19 Vaccine Production By 50% Including Boosters, Supply Other Countries

• Mayo Clinic, nference AI Analysis Find No Real-World Link Between COVID-19 Shots And Clots

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.